Accéder au contenu
Merck
Toutes les photos(1)

Key Documents

324M-1

Sigma-Aldrich

PSA (ER-PR8) Mouse Monoclonal Antibody

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Code UNSPSC :
12352203
Nomenclature NACRES :
NA.41

Source biologique

mouse

Niveau de qualité

100
500

Conjugué

unconjugated

Forme d'anticorps

culture supernatant

Type de produit anticorps

primary antibodies

Clone

ER-PR8, monoclonal

Description

For In Vitro Diagnostic Use in Select Regions (See Chart)

Forme

buffered aqueous solution

Espèces réactives

human

Conditionnement

vial of 0.1 mL concentrate (324M-14)
vial of 0.5 mL concentrate (324M-15)
bottle of 1.0 mL predilute (324M-17)
vial of 1.0 mL concentrate (324M-16)
bottle of 7.0 mL predilute (324M-18)

Fabricant/nom de marque

Cell Marque™

Technique(s)

immunohistochemistry (formalin-fixed, paraffin-embedded sections): 1:50-1:200

Isotype

IgG1κ

Contrôle

prostate

Conditions d'expédition

wet ice

Température de stockage

2-8°C

Visualisation

cytoplasmic

Informations sur le gène

human ... KLK3(354)

Catégories apparentées

Description générale

Prostate-Specific Antigen (PSA) is a 33 kDa protein primarily produced by the prostatic epithelium and the epithelial lining of the periurethral glands . PSA is strongly expressed in both normal and neoplastic prostatic tissue. Although PSA can be considered prostate-specific, PSA and/or PSA gene expression has been detected at low levels in some extra-prostatic tissues such as normal breast tissue, breast tumors, endometrium, adrenal neoplasms and renal cell carcinomas. Anti-PSA is most useful in determining the prostatic origin of carcinomas in non-prostate tissues (metastatic disease) using IHC techniques. This product is best used in conjunction with a panel of antibodies as, up to 27% of prostate carcinoma cases (predominantly poorly differentiated carcinomas) can be negative for this marker.

Qualité


IVD
IVD
RUO
RUO

Liaison

PSA Positive Control Slides, Product No. 324S, are available for immunohistochemistry (formalin-fixed, paraffin-embedded sections).

Forme physique

Solution in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide

Notes préparatoires

Download the IFU specific to your product lot and formatNote: This requires a keycode which can be found on your packaging or product label.

Autres remarques

For Technical Service please contact: 800-665-7284 or email: service@cellmarque.com

Informations légales

Cell Marque is a trademark of Merck KGaA, Darmstadt, Germany

Vous ne trouvez pas le bon produit ?  

Essayez notre Outil de sélection de produits.

Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

U H Stenman et al.
Seminars in cancer biology, 9(2), 83-93 (1999-04-15)
Prostate specific antigen (PSA) is serine protease produced at high concentrations by normal and malignant prostatic epithelium. It is mainly secreted into seminal fluid, where it digests the gel forming after ejaculation. Only minor amounts of PSA leak out into
K A Alanen et al.
Pathology, research and practice, 192(3), 233-237 (1996-03-01)
Immunohistochemical detection of prostate specific antigen (PSA) in metastases of adenocarcinomas is widely used as an aid to identify the prostatic origin of metastatic cells. However, on the one hand, PSA may not be expressed in some poorly differentiated prostatic
M Varma et al.
Histopathology, 47(1), 1-16 (2005-06-29)
Varma M & Jasani B (2005) Histopathology47, 1-16 Diagnostic utility of immunohistochemistry in morphologically difficult prostate cancer: review of current literatureImmunohistochemistry is widely used to distinguish prostate cancer from benign mimics and to establish the prostatic origin of poorly differentiated
T J Polascik et al.
The Journal of urology, 162(2), 293-306 (1999-07-20)
Many advances have occurred during the last decade in the clinical use of prostate specific antigen (PSA) for detecting, staging and monitoring prostate cancer. We review the clinical usefulness and limitations of serum PSA as a tumor marker of prostate

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique